Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    "Cystinosis"
Show Display Options
Rank Status Study
1 Unknown  A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications
Condition: Cystinosis
Intervention: Other: Cysteamine bitartrate
2 Completed New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis
Condition: Cystinosis
Intervention: Drug: Cysteamine
3 Recruiting Use of Cysteamine in the Treatment of Cystinosis
Condition: Cystinosis
Intervention: Drug: Cysteamine
4 Completed
Has Results
Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
Condition: Cystinosis
Intervention: Drug: Cysteamine
5 Active, not recruiting Open-Label Safety & Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cystinosis
Condition: Cystinosis
Interventions: Drug: RP103 Q12H;   Drug: Cystagon Q6H
6 Active, not recruiting Safety/Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
Condition: Cystinosis
Intervention: Drug: RP103 Q12H
7 Completed Kidney Transplantation in Patients With Cystinosis
Condition: Cystinosis
Intervention:
8 Completed Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis
Condition: Cystinosis
Intervention: Other: analysis of pigmentation
9 Completed The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients
Condition: Cystinosis
Interventions: Other: Challenge agent: capsaicin;   Other: Challenge agent: placebo;   Device: Mechanical stimulation with Von Frey filaments;   Device: Temperature sensitivity measurement with Advanced Thermal Stimulation
10 Completed
Has Results
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
Condition: Cystinosis
Interventions: Drug: Cystagon®;   Drug: RP103
11 Completed
Has Results
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
Condition: Cystinosis
Interventions: Drug: Cystagon® (Cysteamine Bitartrate);   Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
12 Completed Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis
Condition: Cystinosis
Intervention:
13 Completed Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis
Condition: Cystinosis
Intervention: Drug: cysteamine hydrochloride
14 Completed N Acetyl Cysteine for Cystinosis Patients
Conditions: Renal Disease;   Cystinosis
Intervention: Drug: N acetyl cysteine
15 Withdrawn Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis
Conditions: Cystinosis;   Myopathy
Intervention: Drug: rh Growth Hormone
16 Active, not recruiting Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Condition: Cystinosis
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
17 Recruiting Cure Cystinosis International Registry
Conditions: Cystinosis;   Nephropathic Cystinosis;   Renal Fanconi Syndrome
Intervention:
18 Recruiting Biomarker for Patient With Cystinosis Disease or Highly Suspected for Cystinosis Disease
Conditions: Cystine Storage Disease;   Cystinosis, Nephropathic;   Lysosomal Cystine Transport Protein, Defect Of
Intervention:
19 Completed The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study
Conditions: Pseudotumor Cerebri;   Cystinosis
Intervention:
20 Completed Evaluation of Fanconi Syndrome and Cystinosis
Conditions: Cystinosis;   Fanconi Syndrome
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.